Buhlmann Diagnostics
Business Services · New Hampshire, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
105 State Rte 101a Unit 1, Amherst, New ...Phone Number
(603) 732-0675Website
www.buhlmannlabs.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
2
1
1
About Buhlmann Diagnostics
BUHLMANN Diagnostics Corp specializes in in vitro diagnostic products, offering a wide range of assays and solutions for various medical fields including gastroenterology, autoimmunity, and neuroimmunology. Their product lineup features innovative tools such as calprotectin assays, elastase tests, and allergy diagnostics, aimed at supporting clinical and research laboratories. The company is dedicated to providing exceptional sales, support, and technical services to its clients, which include clinical, discovery, and basic science research laboratories. With a commitment to quality and innovation, BUHLMANN Diagnostics has been a trusted source in the diagnostic industry for nearly 50 years.Explore more
Buhlmann Diagnostics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Buhlmann Diagnostics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Buhlmann Diagnostics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Buhlmann Diagnostics launches new products
Earning: See what the market has to say on Buhlmann Diagnostics recently announced quarterly report
Funding: Get notified immidiatlly once Buhlmann Diagnostics has new funding data
Check out if Buhlmann Diagnostics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Buhlmann Diagnostics
Check if Buhlmann Diagnostics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Buhlmann Diagnostics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Buhlmann Diagnostics as Masked Content
Find more new buyers
Compare Similar Companies to Buhlmann Diagnostics
Compare insights from companies similar to Buhlmann Diagnostics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Buhlmann Diagnostics
<$5M
11-50
Private
<$5M
2015
PF
Patrick FenninghamSenior Vice President & General Manager
Company Profile Activity
Activity Insights
Buhlmann Diagnostics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Buhlmann Diagnostics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Buhlmann Diagnostics.
Buhlmann Diagnostics financials insights
Gather financial insights about Buhlmann Diagnostics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$129K
Buhlmann Diagnostics Tech Stack
A closer look at the technologies used by Buhlmann Diagnostics
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Training, Sales, Learning & Development, Search, Laboratory Operations, Medical Education & Training, Medical Research, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Technology, HR Operations, Operations
Promotion
Executive Move
Buhlmann Diagnostics has announced that Collin Shaw has been promoted from Vice President, Business Development to the role of Chief Executive Officer.
Event
will be attending the 2022 AACC Annual Scientific Meeting + Clinical Lab Expo conference as an exhibitor. The event will occur from July 24 to July 28, 2022.
Funding
Buhlmann Diagnostics News & Media
BÜHLMANN Laboratories AG Launches New fPELA® turbo Automated, Random Access Pancreatic Elastase Test
BÜHLMANN fPELA® turbo (FDA Exempt. For in vitro Diagnostic Use) is an in vitro diagnostic assay intended for the quantitation of pancreatic elastase in human stool, is now commercially available in the US. [PR.com]BÜHLMANN Laboratories AG Receives FDA Clearance for CALEX® Cap Fecal Calprotectin Extraction Device
BÜHLMANN CALEX® Cap, a single use tube intended for the preparation of human stool samples to be used with the BÜHLMANN fCAL® turbo, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US. [PR.com]BÜHLMANN Laboratories AG Receives FDA Clearance for Its fCAL® turbo Automated, Random Access Calprotectin Test
BÜHLMANN fCAL® turbo, an in vitro diagnostic assay intended for the quantitation of calprotectin in human stool, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US. [PR.com]BUHLMANN Diagnostics Corp. Announces New Distribution Agreement with Meridian Biosciences, Inc.
BUHLMANN Diagnostics Corp. has embarked on a new partnership with Meridian Bioscience, Inc. for the distribution of the 510(k) cleared, BÜHLMANN fCAL® ELISA, an in vitro diagnostic assay intended for the quantitation of calprotectin in human stool. [PR.com]
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Buhlmann Diagnostics
Sign Up For FreeTo access detailed company insights
BUHLMANN Diagnostics Corp specializes in in vitro diagnostic products, offering a wide range of assays and solutions for various medical fields including gastroenterology, autoimmunity, and neuroimmunology. Their product lineup features innovative tools such as calprotectin assays, elastase tests, and allergy diagnostics, aimed at supporting clinic... Read More
